Boston Scientific (NYSE:BSX) announced Saturday that its pivotal clinical trial for the modular cardiac rhythm management (CRM) system, which comprises its EMPOWER leadless pacemaker, met all safety ...

MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ ...

BOSTON -- A leadless pacemaker reliably communicated with a subcutaneous implantable cardioverter-defibrillator (S-ICD) to deliver anti-tachycardia (ATP) and bradycardia pacing, the MODULAR ATP study ...

Boston Scientific Corporation BSX recently presented favorable six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System — the first modular cardiac rhythm management ...

MANCHESTER, UK — There have been many recent advances in cardiac rhythm management, notably the use of leadless pacemakers and subcutaneous implantable cardioverter defibrillators (S-ICDs), experts ...

Cardiac conditions have been on a constant rise in recent years, particularly in the elderly population. As the cases increase, the need for safer procedures that guarantee greater procedural safety, ...

Cardiologist, Dr. Ray Georgenson, has become the first doctor in Iredell County to successfully perform pacemaker surgery with the AVEIR leadless pacemaker at Iredell Memorial Hospital. “Being the ...

The U.K.’s National Institute for Health and Care Excellence (NICE) recommendation that leadless cardiac pacemakers be used as the standard of care for people with slow heart rhythms (bradyarrhythmias ...

MARLBOROUGH, Mass., May 18, 2024 /PRNewswire/ -- Boston Scientific Corporation (BSX) today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM™ System, ...

(RTTNews) - Boston Scientific Corp. (BSX) announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRM System, the first modular cardiac rhythm management ...